XENE

Xenon Pharmaceuticals Inc

38.65
0.12 (0.31%)
Stock Name Stock Symbol Market Stock Type
Xenon Pharmaceuticals Inc XENE NASDAQ Common Stock
  Price Change Price Change % Stock Price Last Trade
0.12 0.31% 38.65 09:58:41
Open Price Low Price High Price Close Price Previous Close
38.44 38.14 40.36 38.65 38.53
more quote information »

Recent News

Date Time Source Heading
02/6/202309:26EDGARStatement of Changes in Beneficial Ownership (4)
02/6/202309:10EDGARReport of Proposed Sale of Securities (144)
01/6/202306:01GLOBEXenon Pharmaceuticals to Present at the 2023 Jefferies..
27/5/202309:11EDGARStatement of Changes in Beneficial Ownership (4)
25/5/202309:06EDGARReport of Proposed Sale of Securities (144)
12/5/202306:01GLOBEXenon Pharmaceuticals to Present at the 2023 RBC Capital..
10/5/202306:38EDGARQuarterly Report (10-q)
10/5/202306:24EDGARCurrent Report Filing (8-k)
10/5/202306:01GLOBEXenon Pharmaceuticals Reports First Quarter 2023 Financial..
04/5/202306:01GLOBEXenon Pharmaceuticals to Present at the BofA Securities..
03/5/202306:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
28/4/202306:15EDGARProxy Statement (definitive) (def 14a)
24/4/202322:00GLOBEXenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program..
22/4/202306:01GLOBEXenon Pharmaceuticals to Present at the 2023 Bloom Burton &..
18/4/202322:15GLOBEXenon Pharmaceuticals to Present at the 22nd Annual Needham..
25/3/202310:19EDGARStatement of Changes in Beneficial Ownership (4)
23/3/202307:01GLOBEXenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
15/3/202307:46EDGARStatement of Changes in Beneficial Ownership (4)
15/3/202307:45EDGARStatement of Changes in Beneficial Ownership (4)
15/3/202307:33EDGARStatement of Changes in Beneficial Ownership (4)
15/3/202307:28EDGARStatement of Changes in Beneficial Ownership (4)
15/3/202307:26EDGARStatement of Changes in Beneficial Ownership (4)
15/3/202307:04EDGARCurrent Report Filing (8-k)
10/3/202310:22EDGARStatement of Changes in Beneficial Ownership (4)
02/3/202308:44EDGARAnnual Report (10-k)
02/3/202308:31EDGARCurrent Report Filing (8-k)
02/3/202308:01GLOBEXenon Pharmaceuticals Reports Fourth Quarter and Full Year..
23/2/202308:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
14/2/202322:16EDGARAmended Statement of Ownership (sc 13g/a)
11/2/202304:11EDGARAmended Statement of Ownership (sc 13g/a)
10/2/202304:47EDGARAmended Statement of Ownership (sc 13g/a)
09/2/202308:01GLOBEXenon Pharmaceuticals to Present at the SVB Securities..
10/1/202300:00GLOBEXenon Pharmaceuticals Outlines Key Milestone Opportunities..
05/1/202308:01GLOBEXenon Pharmaceuticals to Present at the 41st Annual J.P...
14/12/202208:30EDGARStatement of Changes in Beneficial Ownership (4)
03/12/202200:30GLOBEXenon Pharmaceuticals Provides Updates on Proprietary..
01/12/202208:01GLOBEXenon Pharmaceuticals to Present at the Bank of America..
19/11/202212:50TRMNAnalysts Offer Insights on Healthcare Companies: Catalent..
11/11/202212:51TRMNAnalysts Are Bullish on Top Healthcare Stocks: Medtronic..
10/11/202218:51TRMNAnalysts Offer Insights on Healthcare Companies: Amphastar..
10/11/202208:30GLOBEXenon Pharmaceuticals to Participate in Upcoming Investor..
09/11/202208:38EDGARQuarterly Report (10-q)
09/11/202208:09EDGARCurrent Report Filing (8-k)
09/11/202208:01GLOBEXenon Pharmaceuticals Reports Third Quarter 2022 Financial..
08/11/202208:07EDGARCurrent Report Filing (8-k)
08/11/202200:30GLOBEXenon Pharmaceuticals Strengthens Leadership Team with..
03/11/202223:30GLOBEXenon Pharmaceuticals Announces Launch of XEN1101 Phase 3..
02/11/202207:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
11/10/202223:41TRMNAnalysts’ Top Healthcare Picks: Merck & Company (MRK), Xenon..
02/9/202206:01GLOBEXenon Pharmaceuticals to Present at the Wells Fargo 2022..
Your Recent History
NASDAQ
XENE
Xenon Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com

V: D: 20230602 01:14:17